The purpose of this study is to see if combining the investigational drug BKM120 with fulvestrant is more effective than fulvestrant alone in postmenopausal women with hormone receptor-positive HER2-negative locally advanced or metastatic breast cancer that has continued to grow despite aromatase inhibitor therapy.
BKM120 is an investigational drug that blocks a molecule called PI3 kinase, which appears to function abnormally in many cancers. It is taken orally (by mouth). Fulvestrant is a standard drug used to treat postmenopausal women with hormone receptor-positive breast cancer that has continued growing despite hormonal therapy. It is given via injection.
Women in this study will be randomly assigned to receive fulvestrant with BKM120 or fulvestrant with a placebo.